UPC (Universe Pharmaceuticals) Cash Flow from Financing: $9.73 Mil (TTM As of Sep. 2025)


UPC Universe Pharmaceuticals Inc UPC
62 GF Score
Price $5.79
GF Value $5.18
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Universe Pharmaceuticals Cash Flow from Financing?

Universe Pharmaceuticals UPC -6.53% 62 Cash Flow from Financing is $9.73 Mil as of Sep. 2025. GuruFocus rates UPC with a GF Score™ of 62/100 and a GF Value™ of $5.18 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Sep. 2025, Universe Pharmaceuticals paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $6.67 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Universe Pharmaceuticals spent $6.67 Mil on financial activities for the six months ended in Sep. 2025.


Universe Pharmaceuticals  (NAS:UPC) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Universe Pharmaceuticals's issuance of stock for the six months ended in Sep. 2025 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Universe Pharmaceuticals's repurchase of stock for the six months ended in Sep. 2025 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Universe Pharmaceuticals's net issuance of debt for the six months ended in Sep. 2025 was $-6.67 Mil. Universe Pharmaceuticals spent $6.67 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Universe Pharmaceuticals's net issuance of preferred for the six months ended in Sep. 2025 was $0.00 Mil. Universe Pharmaceuticals paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Universe Pharmaceuticals's cash flow for dividends for the six months ended in Sep. 2025 was $0.00 Mil. Universe Pharmaceuticals received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Universe Pharmaceuticals's other financing for the six months ended in Sep. 2025 was $0.00 Mil. Universe Pharmaceuticals received $0.00 Mil on other financial activities.


Universe Pharmaceuticals Cash Flow from Financing Related Terms


Universe Pharmaceuticals Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Universe Pharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universe Pharmaceuticals Cash Flow from Financing Chart

Universe Pharmaceuticals Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cash Flow from Financing
Get a 7-Day Free Trial 26.58 3.32 -1.39 33.95 9.73

Universe Pharmaceuticals Semi-Annual Data
Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.47 6.07 27.89 16.40 -6.67
UPC
62GF Score
Universe Pharmaceuticals Inc UPC
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Universe Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Universe Pharmaceuticals's Cash from Financing for the fiscal year that ended in Sep. 2025 is calculated as:

Universe Pharmaceuticals's Cash from Financing for the quarter that ended in Sep. 2025 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $9.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of $9.73 Mil mean?
Universe Pharmaceuticals (UPC) has a Cash Flow from Financing of $9.73 Mil as of Sep. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Universe Pharmaceuticals and its competitors.
Is Universe Pharmaceuticals' Cash Flow from Financing too high?
Universe Pharmaceuticals' current Cash Flow from Financing is $9.73 Mil. Overall, Universe Pharmaceuticals has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Cash Flow from Financing compare to CPMD and SHPH?
Universe Pharmaceuticals' Cash Flow from Financing of $9.73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Universe Pharmaceuticals and its competitors. Universe Pharmaceuticals's current Cash Flow from Financing is $9.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.18, compared to a current price of $5.79 — trading 11.8% above its estimated fair value. The current Cash Flow from Financing is $9.73 Mil. Universe Pharmaceuticals' overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Cash Flow from Financing is $9.73 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Universe Pharmaceuticals (UPC) Overvalued in 2026?

Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued. The current stock price of $5.79 is trading 11.8% above its estimated GF Value™ of $5.18. GuruFocus considers Universe Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for UPC:

  • Cash Flow from Financing: $9.73 Mil
  • GF Value™: $5.18 vs. price of $5.79 (11.8% above fair value)
  • GF Score™: 62/100 with 9 warning signs

No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Universe Pharmaceuticals Business Description

Address 265 Jingjiu Avenue, Jinggangshan Economic & Technological Development Zone, Jiangxi, Ji’an, CHN, 343100
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
62GF Score

Get the complete analysis for UPC

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.79
Price
$5.18
GF Value